Medine.co.uk

Amproline 400 Mg/Ml Solution For Use In Drinking Water For Chickens And Turkeys

Issued: June 2016

AN: 01178/2014


SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


AMPROLINE 400 mg/mL solution for use in drinking water for chickens and turkeys


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


One mL of solution contains:

Active substance:

Amprolium (as hydrochloride) ..................................400.0 mg

(equivalent to amprolium hydrochloride) ...................452.0 mg


Excipients:

Sorbic acid (E200) .....................................................0.5 mg


For the full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Solution for use in drinking water

Limpid and yellow solution


4. CLINICAL PARTICULARS

4.1. Target species


Chickens (broilers, pullets, layers and breeder hens), turkeys.


4.2. Indications for use, specifying the target species


In chickens (broilers, pullets, layers and breeder hens), turkeys:

- Treatment of intestinal coccidiosis caused by Eimeria sppsusceptible to amprolium.


4.3. Contraindications


None known

4.4. Special warnings for each target species


As with any antiparasiticide, frequent and repeated use of an antiprotozoal agent of the same class can lead to resistance development.

In case of detection of lack of efficacy during treatment, communicate it to competent national authorities.


4.5. Special precautions for use


i) Special precautions for use in animals

The product is not intended for a preventive use.

This product should be reserved in case of coccidiosis outbreaks due to non-availability of vaccine, in case of lack of efficacy of vaccine and in vaccinated flocks if a severe coccidial challenge is diagnosed before immunity has fully developed.


ii) Special precautions to be taken by the person administering the medicinal product to animals


This product is acidic and may cause irritation to, or corrosion of, the skin, eyes, throat and airways.

Avoid all physical contact with the product, including any vapours.

Do not eat, drink or smoke whilst handling this product.

Wear impervious gloves and protective glasses when handling the product.

The selected protective gloves should satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.

In the case of contact with skin or eyes, wash the affected area with clean running water immediately and remove any contaminated clothes. If irritation persists, seek medical advice and show the label to the physician.

In case of accidental ingestion, rinse the mouth with fresh water, seek medical advice immediately and show the label to the physician

Those with known hypersensitivity to amprolium or to sorbic acid should avoid contact with the product.

Wash hands and exposed skin after use.


iii) Other precautions

Amprolium is classified as a persistent substance in soil.


4.6. Adverse reactions (frequency and seriousness)


None known.


4.7. Use during pregnancy, lactation or lay


Studies in laboratory animals have not produced any evidence of teratogenic effects. The safety of amprolium has not been investigated in laying birds. Use only according to the risk/benefit assessment by the responsible veterinarian.


4.8. Interaction with other medicinal products and other forms of interaction


Amprolium is an anticoccidial belonging to thiamin analogs family. Therefore, the efficacy of amprolium may be reduced during a simultaneous administration of products containing vitamin B-complex.


4.9. Amount(s) to be administered and administration route


Administration in drinking water.

In chickens (broilers, pullets, layers, and breeder hens) and turkeys, the posology is: 20 mg amprolium / kg body weight / day (equivalent to 0.5 mL of oral solution / 10 kg bodyweight/day) for 5 to 7 consecutive days.


For the preparation of medicated water, the body weight of the animals to be treated and their actual daily water consumption should be taken into account. Consumption may vary depending on factors like age, state of health, breed, and husbandry system. To provide the required amount of veterinary medicinal product in ml per litre drinking water the following calculation should be made:


0.05 mL of the product per average bodyweight (kg) number of

kg bodyweight X of the animals to be X animals daily treated

------------------------------------------------------------------------------------------------= mL of oral solution /

………. Litre of drinking water

Total water consumption (L) of the herd at the previous day


Sufficient access to the system of water supply should be available for the animals to be treated to ensure adequate water consumption. No other source of drinking water should be available during the medication period. Medicated drinking water should be replaced every 24 hours.


After the end of the medication period the water supply system should be cleaned appropriately to avoid intake of sub-therapeutic amounts of the active substance.


The veterinary medicinal product should not be used in contact with metal pipework or containers.


4.10. Overdose (symptoms, emergency procedures, antidotes), if necessary


A prolonged use at high doses can produce thiamine deficiency. This deficiency can be compensated by a thiamine intake.


4.11. Withdrawal period


Chickens and turkeys:


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group: antiparasitic products, other antiprotozoal agents, amprolium.

ATCvet code: QP51AX09.

5.1. Pharmacodynamic properties


Amprolium is an anticoccidial which belongs to the thiamine analogues family. Amprolium acts by interfering as a competitive antagonist of thiamine within thiamine transport mechanisms. It interferes in the carbohydrate metabolism required for coccidies multiplication and survival.


In in-vitrostudies it was shown that the uptake of thiamine by schizonts of Eimeria tenellaand by host intestinal cells can occur through passive diffusion or by an active, energy-and pH-dependent process. Amprolium competitively inhibited both systems, however, the parasite was shown to be more sensitive to amprolium than the host.


As shown with Eimeria maximainoculated chicken, the administration of Amprolium resulted in a proportion of morphologically abnormal macrogametes and oocysts which may be considered the reason for a reduced sporulation rate.


5.2. Pharmacokinetic particulars


Amprolium is weakly absorbed after oral administration. Maximum plasma drug concentration is reached 4 hours later.

Amprolium is excreted mainly via faeces.


5.3. Environmental properties


Amprolium is persistent in soil.


6. PHARMACEUTICAL PARTICULARS


6.1. List of excipients


Sorbic acid (E200).

Purified water.


6.2. Incompatibilities


In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.


6.3. Shelf-life


Shelf life of the veterinary medicinal product as packaged for sale: 24 months

Shelf life after first opening the immediate packaging: 4 months

Shelf life after dilution according to directions: 24 hours


6.4. Special precautions for storage


This veterinary medicinal product does not require any special storage conditions.


6.5. Nature and composition of immediate packaging


100 mL and 1 L cans: white and opaque can made of high density polyethylene, closed with a white and opaque cap made of high density polyethylene with a ring and having polyethylene foam inside.

5 L can: white and opaque can made of high density polyethylene closed with a white and opaque cap made of high density polyethylene and having a tamper-proof ring.


Not all pack sizes may be marketed.


6.6. Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Qalian

34 Rue Jean Monnet

Z.I. d’Étriché

BP 20341

49503 Segre Cedex

France


8. MARKETING AUTHORISATION NUMBER


Vm 41623/4001


9. DATE OF FIRST AUTHORISATION


June 2016


10. DATE OF REVISION OF THE TEXT


June 2016


27 June 2016

Page 5 of 5